Sattva S Neelapu

List of Publications by Year
in descending order

175 papers	23,804 citations	17405 63 h-index	8370 147 g-index
179 all docs	179 docs citations	179 times ranked	19891 citing authors

#	Article	IF	Citations
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	13.9	3,865
2	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
3	Chimeric antigen receptor T-cell therapy â€" assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	12.5	1,659
4	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€"2 trial. Lancet Oncology, The, 2019, 20, 31-42.	5.1	1,467
5	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	13.9	1,252
6	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood, 2017, 130, 1800-1808.	0.6	1,084
7	Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nature Medicine, 2011, 17, 983-988.	15.2	946
8	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 69-77.	5.1	518
9	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 2017, 25, 285-295.	3.7	498
10	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2020, 38, 3119-3128.	0.8	481
11	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887.	15.2	321
12	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 2022, 22, 85-96.	10.6	315
13	Double hit lymphoma: the <scp>MD A</scp>nderson <scp>C</scp>ancer <scp>C</scp>enter clinical experience. British Journal of Haematology, 2014, 166, 891-901.	1.2	310
14	Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature, 2014, 507, 513-518.	13.7	303
15	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	5.1	296
16	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 2008, 111, 5530-5536.	0.6	294
17	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncology, The, 2012, 13, 716-723.	5.1	274
18	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1311-1318.	5.1	239

#	Article	IF	Citations
19	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	2.5	238
20	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2022, 23, 91-103.	5.1	236
21	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. Journal of Clinical Oncology, 2011, 29, 2787-2794.	0.8	230
22	Managing the toxicities of CAR Tâ€cell therapy. Hematological Oncology, 2019, 37, 48-52.	0.8	214
23	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	12.5	178
24	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2011, 12, 1222-1228.	5.1	168
25	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 2776-2782.	0.8	162
26	A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. Clinical Cancer Research, 2007, 13, 958-964.	3.2	150
27	Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncology, The, 2016, 17, 622-631.	5.1	149
28	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling, 2016, 9, ra17.	1.6	147
29	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
30	Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. Journal of Clinical Oncology, 2012, 30, 4161-4167.	0.8	137
31	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883.	2.5	134
32	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2009, 27, 3036-3043.	0.8	132
33	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
34	Clinical and pathological characteristics of HIV- and HHV-8â€“negative Castleman disease. Blood, 2017, 129, 1658-1668.	0.6	127
35	Clinical efficacy of anakinra to mitigate CAR T-cell therapyâ€“associated toxicity in large B-cell lymphoma. Blood Advances, 2020, 4, 3123-3127.	2.5	115
36	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	12.5	114

#	Article	IF	Citations
37	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nature Medicine, 2022, 28, 735-742.	15.2	114
38	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica, 2012, 97, 586-594.	1.7	110
39	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 2005, 11, 986-991.	15.2	106
40	Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood, 2012, 119, 161-169.	0.6	103
41	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. Clinical Cancer Research, 2013, 19, 6882-6890.	3.2	103
42	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discovery, 2020, 10, 440-459.	7.7	103
43	Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 2012, 119, 6373-6378.	0.6	97
44	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood, 2021, 137, 3272-3276.	0.6	95
45	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica, 2021, 106, 2667-2672.	1.7	92
46	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 2020, 135, 2106-2109.	0.6	90
47	Phase II Study of Yttrium-90â€“Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 5213-5218.	0.8	87
48	Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood, 2015, 125, 3357-3359.	0.6	87
49	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molecular Oncology, 2015, 9, 2043-2053.	2.1	87
50	Ultraâ€“lowâ€dose radiotherapy for definitive management of ocular adnexal Bâ€cell lymphoma. Head and Neck, 2017, 39, 1095-1100.	0.9	87
51	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021, 138, 1081-1085.	0.6	84
52	Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. British Journal of Haematology, 2009, 147, 515-525.	1.2	83
53	Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. Journal of Controlled Release, 2006, 113, 261-270.	4.8	81
54	Induction of p53â€mediated transcription and apoptosis by exportinâ€1 (<scp>XPO</scp>1) inhibition in mantle cell lymphoma. Cancer Science, 2014, 105, 795-801.	1.7	81

#	Article	IF	Citations
55	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	1.2	81
56	Longâ€term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	1.2	81
57	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	0.6	81
58	CAR-T efficacy: is conditioning the key?. Blood, 2019, 133, 1799-1800.	0.6	79
59	The survival outcome of patients with relapsed/refractory peripheral Tâ€cell lymphomaâ€not otherwise specified and angioimmunoblastic Tâ€cell lymphoma. British Journal of Haematology, 2017, 176, 750-758.	1.2	78
60	Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. Journal of Immunology, 2013, 190, 6681-6693.	0.4	77
61	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen. Clinical Cancer Research, 2004, 10, 8309-8317.	3.2	75
62	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 2016, 101, 531-540.	1.7	75
63	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 2012, 119, 4123-4128.	0.6	70
64	Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer, 2008, 112, 831-836.	2.0	69
65	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951.	2.5	69
66	Detection of circulating tumour <scp>DNA</scp> in patients with aggressive Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2013, 163, 123-126.	1.2	67
67	Encouraging activity for R-CHOP in advanced stage nodular lymphocyteâ€“predominant Hodgkin lymphoma. Blood, 2017, 130, 472-477.	0.6	65
68	Management strategies and outcomes for very elderly patients with diffuse large Bâ€cell lymphoma. Cancer, 2016, 122, 3145-3151.	2.0	61
69	3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. Lab on A Chip, 2017, 17, 407-414.	3.1	60
70	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica, 2013, 98, 1458-1466.	1.7	58
71	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica, 2017, 102, 373-380.	1.7	58
72	CRP and ferritin in addition to the EASIX score predict CAR-Tâ€related toxicity. Blood Advances, 2021, 5, 2799-2806.	2.5	57

#	Article	IF	Citations
73	Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood, 2004, 104, 1961-1969.	0.6	55
74	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629.	2.0	54
75	CAR T-Cell Therapy in Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1065-1065.	13.9	53
76	Chimeric Antigen Receptor T Cells in Hematologic Malignancies. Pharmacotherapy, 2017, 37, 334-345.	1.2	52
77	Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica, 2002, 87, 989-1001.	1.7	51
78	The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British Journal of Haematology, 2014, 165, 112-116.	1.2	50
79	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology, 2015, 171, 726-735.	1.2	50
80	Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood, 2019, 133, 2800-2802.	0.6	49
81	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood, 2021, 137, 1832-1835.	0.6	48
82	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. Blood, 2019, 134, 203-203.	0.6	48
83	Long-Term (â‰¥4 Year and â‰¥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). Blood, 2021, 138, 1764-1764.	0.6	48
84	Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. Blood, 2016, 128, 59-59.	0.6	47
85	Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen. Journal of Immunology, 2013, 190, 4887-4898.	0.4	45
86	The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Practice and Research in Clinical Haematology, 2018, 31, 293-298.	0.7	44
87	Targeting Wnt pathway in mantle cell lymphoma-initiating cells. Journal of Hematology and Oncology, 2015, 8, 63.	6.9	43
88	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	2.5	43
89	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 2022, 107, 690-701.	1.7	43
90	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	2.5	42

#	Article	IF	Citations
91	CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia, 2019, 33, 2640-2653.	3.3	40
92	A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. Journal of Translational Medicine, 2004, 2, 9.	1.8	36
93	Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. JAMA Oncology, 2020, 6, 281.	3.4	36
94	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	5.8	34
95	A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood, 2007, 109, 5160-5163.	0.6	33
96	Safety of CAR T-cell therapy in kidney transplant recipients. Blood, 2021, 137, 2558-2562.	0.6	33
97	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. International Journal of Cancer, 2014, 135, 2834-2846.	2.3	31
98	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	1.0	31
99	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology, 2021, 18, 435-453.	12.5	31
100	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393.	2.6	29
101	Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. British Journal of Haematology, 2008, 142, 179-191.	1.2	28
102	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Advances, 2019, 3, 2400-2408.	2.5	28
103	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood, 2022, 140, 851-860.	0.6	28
104	Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report. Clinical Lymphoma and Myeloma, 2005, 6, 61-64.	2.1	26
105	Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Research, 2010, 5, 212-225.	0.3	26
106	Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplantation and Cellular Therapy, 2021, 27, 930.e1-930.e10.	0.6	24
107	Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.. Blood, 2010, 116, 2812-2812.	0.6	24
108	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Advances, 2022, 6, 2867-2871.	2.5	24

#	Article	IF	Citations
109	BiovaxIDâ„¢: a personalized therapeutic cancer vaccine for non-Hodgkinâ€™s lymphoma. Expert Opinion on Biological Therapy, 2007, 7, 113-122.	1.4	23
110	Positron emission tomographyâ€“computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Advances, 2018, 2, 1334-1343.	2.5	23
111	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica, 2020, 105, 1907-1913.	1.7	23
112	Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood, 2019, 134, 765-765.	0.6	23
113	Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).. Blood, 2007, 110, 2566-2566.	0.6	22
114	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. Journal of Clinical Oncology, 2021, 39, 456-466.	0.8	21
115	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers, 2021, 13, 2782.	1.7	21
116	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Advances, 2022, 6, 1143-1151.	2.5	21
117	Chimeric Antigen Receptorâ€“Engineered T Cell Therapy in Lymphoma. Current Oncology Reports, 2019, 21, 38.	1.8	20
118	Chimeric antigen receptor Tâ€cell therapy toxicities. British Journal of Clinical Pharmacology, 2021, 87, 2414-2424.	1.1	19
119	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Frontiers in Oncology, 2021, 11, 648655.	1.3	19
120	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Advances, 2022, 6, 2757-2762.	2.5	19
121	Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood, 2022, 140, 504-515.	0.6	19
122	Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Review of Vaccines, 2006, 5, 381-394.	2.0	18
123	A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood, 2007, 109, 5407-5410.	0.6	18
124	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Current Opinion in Oncology, 2015, 27, 384-391.	1.1	18
125	IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. OncoImmunology, 2016, 5, e1237327.	2.1	17
126	Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. , 2019, 7, 126.		17

#	Article	IF	Citations
127	COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT. Korean Journal of Radiology, 2021, 22, 1938.	1.5	17
128	Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer, 2018, 18, 187.	1.1	16
129	Stage I Nonâ€Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. British Journal of Haematology, 2019, 185, 334-338.	1.2	16
130	A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones. Journal of Immunological Methods, 2008, 331, 13-26.	0.6	15
131	High tenâ€year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (Râ€<scp>FND</scp>) with interferon maintenance in indolent lymphoma: Results of a randomized Study. British Journal of Haematology, 2017, 177, 263-270.	1.2	14
132	Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica, 2021, 106, 1504-1506.	1.7	14
133	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature Communications, 2022, 13, 2228.	5.8	14
134	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Seminars in Oncology Nursing, 2021, 37, 151216.	0.7	13
135	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 789-796.	0.6	12
136	CAR-T failure: beyond antigen loss and T cells. Blood, 2021, 137, 2567-2568.	0.6	12
137	Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Annals of Hematology, 2019, 98, 1169-1176.	0.8	11
138	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
139	PD-1 Expression Is Markedly Upregulated on Intratumoral CD4+ and CD8+ T Cells in Follicular Lymphoma and Is Associated with T-Cell Exhaustion.. Blood, 2007, 110, 2749-2749.	0.6	10
140	Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies. Hematology American Society of Hematology Education Program, 2007, 2007, 243-249.	0.9	9
141	Targeting Human B-cell Malignancies through Ig Light Chainâ€“Specific Cytotoxic T Lymphocytes. Clinical Cancer Research, 2011, 17, 5945-5952.	3.2	9
142	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. Current Oncology Reports, 2015, 17, 30.	1.8	9
143	Vaccination strategies in follicular lymphoma. Current Hematologic Malignancy Reports, 2009, 4, 189-195.	1.2	8
144	Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. International Journal of Infectious Diseases, 2021, 112, 327-329.	1.5	8

#	Article	IF	Citations
145	Therapeutic Vaccine for Lymphoma. Yonsei Medical Journal, 2007, 48, 1.	0.9	7
146	Frontline antibiotic therapy for earlyâ€stage Helicobacter pylori â€negative gastric MALT lymphoma. American Journal of Hematology, 2019, 94, E150-E153.	2.0	7
147	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61.	0.2	7
148	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood, 2021, 137, 1124-1129.	0.6	7
149	A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.. Blood, 2009, 114, 1714-1714.	0.6	7
150	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 753-759.	0.2	6
151	Anti-PD-1 antibodies for the treatment of B-cell lymphoma. OncoImmunology, 2014, 3, e28101.	2.1	5
152	Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells. OncoImmunology, 2016, 5, e1232220.	2.1	5
153	Primary mediastinal large Bâ€cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. British Journal of Haematology, 2020, 190, e114-e117.	1.2	5
154	Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19). , 2017, , .		5
155	SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy. Blood, 2014, 124, 1629-1629.	0.6	5
156	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia and Lymphoma, 2020, 61, 1380-1387.	0.6	4
157	Targeting the tumor niche to treat cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12907-12908.	3.3	3
158	Not So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction. Cancer Discovery, 2020, 10, 492-494.	7.7	3
159	Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study. Blood, 2018, 132, 447-447.	0.6	3
160	Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Blood, 2019, 134, 1583-1583.	0.6	3
161	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposome Encapsulated Lymphoma Membrane Proteins.. Blood, 2004, 104, 749-749.	0.6	3
162	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood, 2016, 128, 5628-5628.	0.6	3

#	Article	IF	Citations
163	Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel. Blood, 2020, 136, 16-17.	0.6	3
164	SIRPÎ±+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Advances, 2022, 6, 3286-3293.	2.5	3
165	Editorial: CAR T-Cell Therapies in Hematologic Tumors. Frontiers in Oncology, 2020, 10, 588134.	1.3	2
166	Targeting CAR T Resistance Due to CD19 Loss with CD79b-Specific CAR T Cells in B-Cell Malignancies. Blood, 2018, 132, 1662-1662.	0.6	2
167	Reply. Biology of Blood and Marrow Transplantation, 2019, 25, e211-e212.	2.0	1
168	Prolonged neurotoxicity in a lymphoma patient after CD19â€directed CAR Tâ€cell therapy: A case report and brief review of the literature. Advances in Cell and Gene Therapy, 2021, 4, e104.	0.6	1
169	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. Cancer Drug Discovery and Development, 2022, , 207-219.	0.2	1
170	Therapy of newly diagnosed follicular lymphoma. Frontiers in Oncology, 2012, 2, 188.	1.3	0
171	Rush Hour Traffic: Directing T Cells to Tumor. Journal of the National Cancer Institute, 2014, 106, dju301-dju301.	3.0	0
172	A CAR against CAR for unintended consequences. Blood, 2020, 135, 460-462.	0.6	0
173	Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.. Blood, 2009, 114, 465-465.	0.6	0
174	Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. Blood, 2011, 118, 2643-2643.	0.6	0
175	Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood, 2013, 122, 3028-3028.	0.6	0